Amalgamated Bank Buys 2,459 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Amalgamated Bank boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 52.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,152 shares of the company’s stock after buying an additional 2,459 shares during the period. Amalgamated Bank’s holdings in Recursion Pharmaceuticals were worth $54,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RXRX. Mubadala Investment Co PJSC purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $128,041,000. Capstone Investment Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $161,000. UBS Group AG grew its position in shares of Recursion Pharmaceuticals by 101.9% during the fourth quarter. UBS Group AG now owns 691,911 shares of the company’s stock worth $6,822,000 after purchasing an additional 349,232 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Recursion Pharmaceuticals by 45.2% during the 1st quarter. Russell Investments Group Ltd. now owns 158,305 shares of the company’s stock valued at $1,578,000 after purchasing an additional 49,292 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Recursion Pharmaceuticals by 12.6% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock worth $103,317,000 after purchasing an additional 1,159,023 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total value of $83,792.04. Following the completion of the transaction, the director now owns 7,167,110 shares of the company’s stock, valued at approximately $52,463,245.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total transaction of $83,792.04. Following the completion of the transaction, the director now owns 7,167,110 shares of the company’s stock, valued at $52,463,245.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the sale, the chief operating officer now directly owns 535,457 shares in the company, valued at approximately $4,353,265.41. The disclosure for this sale can be found here. In the last 90 days, insiders sold 231,682 shares of company stock valued at $1,632,044. 15.75% of the stock is owned by company insiders.

Recursion Pharmaceuticals Stock Down 6.4 %

Shares of RXRX stock opened at $6.17 on Wednesday. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $15.74. The stock has a fifty day simple moving average of $6.95 and a two-hundred day simple moving average of $8.12. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same quarter last year, the business posted ($0.38) earnings per share. The company’s quarterly revenue was up 30.9% compared to the same quarter last year. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on RXRX shares. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Needham & Company LLC dropped their price objective on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group reduced their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Leerink Partners decreased their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.